What is OxyDial?
OxyDial Inc. operates at the intersection of advanced medical diagnostics and digital health infrastructure. The company is currently engineering a sophisticated Oxygen-Hemoglobin Equilibrium blood testing instrument, designed to provide high-precision data in a portable format. By integrating this hardware with a robust cloud-based platform, OxyDial aims to streamline the diagnostic process for complex blood disorders and genetic conditions. This dual-pronged approach addresses the critical need for faster, more accessible testing solutions within both clinical and research environments, positioning the company as a key innovator in the medical technology sector.
How much funding has OxyDial raised?
OxyDial has raised a total of $700K across 1 funding round:
Stock/Share Issuance
$700K
Stock/Share Issuance (2026): $700K, investors not publicly disclosed
Key Investors in OxyDial
OxyDial
Undisclosed investor participating in the funding round.
OxyDial
Undisclosed investor participating in the funding round.
OxyDial
Undisclosed investor participating in the funding round.
What's next for OxyDial?
With this major enterprise-level funding, OxyDial is expected to transition from the research and development phase toward commercialization and clinical validation. The strategic allocation of capital will likely focus on scaling manufacturing capabilities for their diagnostic instruments and expanding the cloud platform's analytical capacity. As the company moves forward, the focus will remain on securing regulatory milestones and establishing partnerships with healthcare providers to integrate their technology into standard diagnostic protocols. This growth phase is critical for establishing OxyDial as a leader in portable, high-fidelity blood analysis, ultimately aiming to improve patient outcomes through superior diagnostic speed and accuracy.
See full OxyDial company page
